Abstract |
A total of 18 patients with locally advanced (Stage III) adenocarcinoma and large cell undifferentiated carcinoma of the lung, previously untreated, were enrolled in a Phase II trial. Treatment consisted of carboplatin 325 mg/m2, day 1 and etoposide 100 mg/m2 on days 2 and 3. All patients were evaluable for response. Of these, one patient had a partial response (5.5%; confidence interval 0-24%). Toxicity comprised mainly leukopenia and anaemia. Other toxicities were mild. This Phase II study evidenced a poor response rate for these regimes on adenocarcinoma and large cell undifferentiated carcinoma of the lung.
|
Authors | R Fuentes, J Dorca, E Canals, A Izquierdo, M Beltrán, P Viladiu |
Journal | Lung cancer (Amsterdam, Netherlands)
(Lung Cancer)
Vol. 12
Issue 3
Pg. 259-62
(Jun 1995)
ISSN: 0169-5002 [Print] Ireland |
PMID | 7655835
(Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article)
|
Chemical References |
|
Topics |
- Adenocarcinoma
(drug therapy)
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Carboplatin
(administration & dosage, adverse effects)
- Carcinoma, Large Cell
(drug therapy)
- Etoposide
(administration & dosage, adverse effects)
- Female
- Humans
- Lung Neoplasms
(drug therapy)
- Male
- Middle Aged
|